Page numbers followed by b, f, and t indicate boxes, figures, and tables, respectively.
(p. 861)
Abstinence versus harm-minimization prevention programs, 581–
582
Abuse child neuroendocrine changes, 41 suicidal behavior and, 490–
491 physical, suicidal behavior and, 490–
491
Acamprosate for alcohol use disorders, 446
Accountable care organizations (ACOs), 609
Acculturation, eating disorders and, 350
Acute stress disorder, 270
Acute versus chronic care, 621,
629
ADAPT (Antidepressant and Psychotherapy trial), 51–
52
Adolescent Brain Cognitive Development (ABCD) study, 378,
636
Adolescent Suicide Awareness Program (ASAP), 504
Adrenal hormones and adolescent behavior, 119
Adverse Childhood Experiences Study, 75
After-school programs for positive youth development, 556,
559,
560–
561b
Alaskan Natives, suicide rate of, 485
Alcohol dehydrogenase, 385
Alcohol use and abuse alcohol dependence as adult, 428 cultural and societal factors in, 413 general description of, 406–
407 Internet addiction and, 589 risk and protective factors for, 413–
415 suicidal behavior and, 488–
489
Alcohol use disorders (AUDs) issues in determining, 412–
413
Alprazolam for panic disorder, 247
Amazing Chateau gambling prevention program, 583t
Amenorrhea in anorexia nervosa, 308
American Foundation for Suicide Prevention, 499
(p. 862)
American Society for Addiction Medicine (ASAM), 626
Amygdala developmental changes, 204 extended, in drug addiction, 375
Animal models of substance use disorders, 373–
376,
374f
Anorexia nervosa. See alsoEating disorders binge eating/purging subtype, 291,
292b combination therapy for, 324–
325 cross-cultural studies, 349–
350 diagnostic migration, 304,
365 outpatient treatment, 326 prevention programs, 353–
361 in high-risk populations and settings, 359–
361 psychosocial therapy, 316–
320 randomized controlled trials, 316–
319 restricting subtype, 291,
292b risk factors for, 336–
342 behavioral/environmental, 339–
342 eating and weight-related, 339–
340
Antepartum depression, 47–
48
Anticonvulsants, schizophrenia and, 150
Antidepressant and Psychotherapy trial (ADAPT), 51–
52
Antidepressants. See also specific drugs for anorexia nervosa, 321 for binge-eating disorder, 323 for generalized anxiety disorder, 225 heterocyclic, for major depressive disorder, 57 for major depressive disorder in children and adolescents, 59–
61 combination and augmentation therapy, 57–
58 prevention of relapse and recurrence, 58 selective serotonin and noradrenaline reuptake inhibitor, for major depressive disorder, 56 tricyclic for generalized anxiety disorder, 224,
225 for major depressive disorder in adults, 57
Antipsychotics. See also specific drugs atypical for bipolar disorder, with mood stabilizers, 65–
66 for treatment-resistant depression, 527–
528 for bipolar disorder, 455 for major depressive disorder, 58,
61
Anxiety disorders autonomic nervous system abnormalities, 206,
254–
255 biological correlates, 206–
211 brain developmental changes, 203–
205 cognitive-behavioral therapy, 215–
216 developmental considerations, 216 education and skill-building, 215
(p. 863)
history and rationale, 214–
216 comorbidities, 197–
198,
197t alcohol use disorders, 415 binge-eating disorder, 348 substance use disorder, 456–
457 criminal behavior and, 261–
262 disability requirement, 196 electroencephalography, 208–
209 emotional processing theory, 200 environmental factors, 256–
564 etiology and maintenance theories, 199–
201 exposure therapy, mechanisms, 199–
201 fear structures cognitive-behavioral therapy and, 214 emotional processing theory and, 200 gambling behavior and, 577 gender differences in, 196–
197 generalized in children and adolescents, 224–
226 treatment in children and adolescents, 224–
226 management of partial response and nonresponse to, 246 Internet addiction for coping with, 588–
589 learning theories for, 199–
201 pharmacotherapy with cognitive-behavioral therapy, 218–
219 prevention of, 252–
280 early detection and screening, 264–
269 risk factors and protective factors, 253–
264,
265t theoretical and conceptual models, 252–
253 prevention programs for, 269–
275 signs and symptoms of, 194–
195t suicidal behavior and, 489 trauma exposure, adolescence and, 262–
263 treatment, xxii,
214–
249 management of partial response and nonresponse to, 246
Anxiety Disorders Interview Schedule for Children, 269
Applied Suicide Intervention Skills Training (ASIST), 501–
502
(p. 864)
Aripiprazole for anorexia nervosa, 322 for conduct disorder with substance use disorder, 456 for major depressive disorder, 58
Arnarson and Craighead program for prevention of depression, 79–
80
ASAM .5 Level of Care,
626
Asian Americans substance use disorders, 385
Association studies in schizophrenia, 126–
128
Asthma, depression and, 17
Atomoxetine for ADHD with substance use disorder, 454
Attachment as outcome of positive youth development, 549 security in, depression and, 25 styles, anxiety disorders and, 256–
258
Attachment-based family therapy for major depressive disorder, 53 for suicidal behavior, 523–
524
Attentional threat bias in anxiety disorders, 201–
202
Attention-deficit/hyperactivity disorder (ADHD), comorbidities alcohol use disorder, 414 substance use disorder, 453–
454
Attention deficit in children of schizophrenic parents, 170–
171,
172
Attributional style, pessimistic suicidal behavior and, 489 and vulnerability to depression, 20–
21
Attributions, stigma and, 602
Australia depression prevention programs, 78–
79 national youth development policy of, 636
Autism Centers of Excellence, 617
Autistic spectrum disorders, suicidal behavior and, 489
Automobile accidents, alcohol-related, 411
Autonomic nervous system abnormalities, anxiety disorders and, 206,
254–
255
Avoidant/restrictive food intake disorder, 295
Baclofen for bulimia nervosa, 323
Ballet dancers, anorexia nervosa in, 341,
359
Beardslee program for prevention of depression, 80–
83
A Beautiful Mind (film), 605
Behavioral inhibition and anxiety disorders, 255 selective prevention intervention for, 272
Benzodiazepines for generalized anxiety disorder, 224 for separation anxiety disorder, 227
Benztropine for schizophrenia, 147t
“Beyondblue” extensive universal program, 78–
79
Big Brothers and Big Sisters, 558b
Binge eating in anorexia nervosa, 291,
292b
Binge-eating disorder prevention programs for, 353–
361 in high-risk populations and settings, 359–
361
(p. 865)
Bio-ecological approach to youth development, 546
Bipolar disorder community attitudes toward, 601 family history and, 34–
35 hypothalamic-pituitary-adrenal axis hyperactivity, 40–
41 pharmacotherapy combination therapy, 66–
67 prevention programs for, 86 prevention research agenda, 95–
96 psychosocial therapy, 62–
63 suicidal behavior and, 488 treatment research agenda, 95
Bipolar Offspring Study (BIOS), 36
Birth cohort studies in schizophrenia, 166,
172
Blood alcohol level (BAL), 407–
408
Body dissatisfaction anorexia nervosa and, 340
Body fat, fear of, as criterion for anorexia nervosa, 291
Body mass index anorexia nervosa and, 338 binge-eating disorder, 347
Bonding, in positive youth development, 549
Bone mineral density in anorexia nervosa, 311
Borderline personality disorder, plus suicidal behavior, dialectical behavioral therapy for, 522
Botvin’s life skills training program, 473
Brain. See also Neurobiology;
specific parts of brain abnormalities in children of schizophrenic parents, 177 violence exposure and, 75 executive inhibitory circuitry defects, in substance use disorders, 377 imaging in substance use disorders, 379–
382 reward center dysregulation, 376
Brexpiprazole for major depressive disorder, 58
Brief dynamic therapy for major depressive disorder, 48
Brief strategic family therapy for substance use disorders, 435–
436
Bulimia nervosa. See alsoEating disorders combination therapy for, 324–
325 cross-cultural studies on, 349 diagnostic migration, 304 internet-based relapse prevention, 329–
330
Bullying binge-eating disorder and, 348 suicidal behavior and, 491–
492
Buprenorphine for opioid addiction, 446–
447,
451
Bupropion for ADHD plus substance use disorder, 454 for major depressive disorder, 57,
60–
61 for smoking cessation, 446,
449
Buspirone for generalized anxiety disorder, 225
Calcium supplementation in anorexia nervosa, 311
Caloric requirements, 290
Carbamazepine for bipolar disorder in adolescents, 65,
67
Cardiovascular system in eating disorders, 306t
Caring, positive youth development and, 550
Caring for Children in the Community Study, 13
Caring for Children Study, 5t
Caring School Community, 558b
Case identification in mental health disorders, 71–
72,
86 in substance use disorders, 622
CASI (Childhood Anxiety Sensitivity Index), 201,
267
CAST (Coping and Support Training), 516
Catechol-O-methyl transferase (COMT) as schizophrenia susceptibility gene, 128,
129
CBCL (Child Behavior Checklist), 269
C-CARE (Counselors Care), 516–
517
CCI (Comprehensive College Initiative), 499
CEEBIT (Continuous Evaluation of Evolving Behavioral Intervention Technology), 612
Center for Prevention Research, 71
Centers of Excellence, 609,
617
Cerebellum, developmental changes in, 204–
205
Character, positive youth development and, 550
Chemical transmission in anxiety disorders, 217
Child abuse neuroendocrine changes, 41 suicidal behavior and, 490–
491
Child and Adolescent Trauma Screen (CATS), 267–
268
Child Behavior Checklist (CBCL), 269
Childhood Anxiety Sensitivity Index (CASI), 201,
267
Child PTSD Symptom Scale (CPSS), 267–
268
Children. See alsoParent-child interaction bipolar disorder in, 30–
31,
63 generalized anxiety disorder in, 224–
226 major depressive disorder in versus adolescent-onset, 4,
6,
7 antidepressants for, 59–
61 psychosocial therapy, 50–
61 obsessive-compulsive disorder in, 232–
238 post-traumatic stress disorder in, 238–
242 schizophrenia in, event-related potentials in, 115–
119,
117t social anxiety disorder in, 220–
221
Children’s Health Insurance Program Reauthorization Act of 2009 (CHIPRA), 608–
609
Chlorpromazine for schizophrenia, 148t,
152t
CHRNA7 as schizophrenia susceptibility gene,
128,
129
Chronic versus acute care, 621,
629
Citalopram for major depressive disorder, 56,
59,
455
Clarke program for prevention of depression, 83–
84
Classical conditioning in substance use disorders, 376
Clean Break gambling prevention program, 583t
Clomipramine for obsessive-compulsive disorder, 232,
235 for separation anxiety disorders, 227
(p. 867)
Clozapine for psychotic disorder and suicidal behavior, 150 for suicide attempters, 528
CNV in schizophrenia, 116
Cognitive-behavioral therapy for anorexia nervosa, 327 for anxiety disorders developmental considerations, 216 education and skill-building, 215 history and rationale, 214–
216 for binge-eating disorder, 328–
329 delivery, advances in, 614–
615 for Internet addiction, 594–
595 for major depressive disorder in children and adolescents, 50–
54 for positive youth development, 554 for separation anxiety disorder, 219t,
226–
227
Cognitive diathesis-stress model of depression, 20–
22
Cognitive remediation therapy for schizophrenia, 137–
138
CollegeResponse program, 499
Columbia TeenScreen Program (CTSP), 498–
499
Combined drug and psychosocial treatments major depressive disorder, 57–
58
Communities That Care (CTC), 558b,
612
Community attitudes toward mental illness, 601 depression prevention interventions in, 56,
88 positive youth development programs, 558b,
559,
559b therapeutic, for substance use disorders, 429
Community environmental interventions for substance abuse prevention, 470
Community factors in anxiety disorders, 260–
261
Community Partners in Care, 612
Competence, positive youth development and, 549–
550
Competencies as outcome of positive youth development, 554–
555
Compliance therapy for schizophrenia, 141
Comprehensive College Initiative (CCI), 499
Compulsive disorders in drug addiction, 373,
374f
Conditioning, classical in substance use disorders, 376
Conduct disorder, comorbidities alcohol use disorders, 414 substance use disorders, 456
Confidence, positive youth development and, 550–
551
Confidentiality online treatment of mental disorders, 615 in suicide screening programs, 499
Connection, positive youth development and, 549
Consent for services, minor, 630–
631
Contact effects in reducing stigma of mental illness, 603–
604
Contagion anxiety disorders and, 277
Contingency management incentive systems for substance use disorders, 437
Contingent negative variation (CNV) in schizophrenia, 116,
117t
Continuing care for substance use disorders, 629–
630
Continuous Evaluation of Evolving Behavioral Intervention Technology (CEEBIT), 612
Contribution, positive youth development and, 551
Control, perceived, in anxiety disorders, 256
Coping and Support Training (CAST), 516
Coping skills strategies in anxiety disorders, 255–
256
Coping With Depression for Adolescents (CWD-A) intervention, 52–
53
Corticostriatal circuitry in schizophrenia, 122–
123
Corticotropin-releasing factor in stress response, 40–
41 in substance use disorder, 375
Cortisol and dopamine activity, 120
Counseling genetic, in schizophrenia, 130–
131
Counselors Care (C-CARE), 516–
517
Course of Subthreshold Bipolar Disorder in Youth (COBY), 30,
38–
39
CPSS (Child PTSD Symptom Scale), 267–
268
Cravings in drug addiction, 374
Credentialing process, substance abuse treatment and, 628
Cross-cultural studies, 349–
351
Cross-National Collaborative Group study, 32
CTSP (Columbia TeenScreen Program), 498–
499
CWD-A intervention, 52–
53
DARE (Drug Abuse Resistance Education), 466–
467
Delay discounting in substance use disorder, 382
Depression with atypical features, 9 bereavement exclusion, 10–
11 brain abnormalities associated with, 42–
44,
75 cognitive diathesis-stress model, 21–
22 gambling behavior and, 577 hypothalamic-pituitary-adrenal axis hyperactivity, 40–
41 Internet addiction for coping with, 588–
589 interpersonal vulnerability and, 25–
28 major cognitive vulnerability to, 21–
22 combination therapy for, 57–
58 community attitudes toward, 601 comorbidities, 17 alcohol use disorders, 414 binge-eating disorder, 348 impact on treatment outcome, 52 dysthymic disorder versus, 9–
10 interpersonal vulnerability to, 25–
28 personality/temperament and, 18–
20
(p. 869)
prepubertal and adolescent-onset, 6–
8 prevention programs, 70–
88 future directions and recommendations, 86–
88 psychosocial therapy for children and adolescents, 50–
61 race/ethnicity and, 28–
29 relationship to schizophrenia, 125–
126 socioeconomic status and, 28 treatment research agenda, 91–
93 maternal offspring depression and, 17–
18,
27 response to cognitive-behavioral therapy and, 51 with melancholic features, 8 parental, offspring depression and, 17–
18,
27,
80–
83 self-propagating nature of, 566 specific vulnerability hypothesis and, 24–
25 subsyndromal, as risk factor for, 74 treatment-resistant, 57–
58
Depression Improvement Across Minnesota–Offering a New Direction (DIAMOND), 612
Desvenlafaxine for major depressive disorder, 56,
60
Development youth bio-ecological approach, 546 problem-centered approach, 546–
547
Developmental assets in positive youth development, 546
Developmental group therapy for suicidal youth, 522
Developmental milestones in schizophrenia, premorbid abnormalities, 161–
162,
161–
163t,
173
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria generalized anxiety disorder, 197 posttraumatic stress disorder, 260,
268
Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria
alcohol use disorder, 412 bipolar disorders in youth, 30–
32 depressive disorder criteria changes, 10–
11 disruptive mood dysregulation disorder (DMDD), 7 major depressive disorder (MDD), 8–
9 substance use disorder, 392
Diagnostic Questionnaire for Internet Addiction, 587
Dialectical behavioral therapy
Dieting. See alsoWeight loss anorexia nervosa and, 339 binge-eating disorder and, 347
Disorder, harmful dysfunction account of, 191–
192
Disorganization in schizophrenia, 105
Disruptive behavior disorders plus depression, 17
Disruptive mood dysregulation disorder (DMDD), xxi,
7,
11
Dissemination and implementation (D&I) research, 610–
612
Disulfiram for alcohol use disorders, 446,
450
Divalproex for bipolar disorder maintenance therapy, 67–
68 for conduct disorder with substance use disorder, 456
Don’t Bet on It gambling prevention program, 583t
Dopamine in binge-eating disorder, 346 impulsive behavior and, 383
Dot Probe Attention Allocation Task, 202
Dove media campaign to encourage self-esteem, 360
Drug Abuse Resistance Education (DARE), 466–
467
Duloxetine for major depressive disorder, 56,
60–
61
Dysbindin as schizophrenia susceptibility gene, 128
Eating disorders. See alsoAnorexia nervosa;
Binge-eating disorder;
Bulimia nervosa avoidant/restrictive food intake disorder, 295 combination therapy for, 324–
325 community attitudes toward, 601 diagnostic migration, 304,
365 prevention programs for, 353–
361 in high-risk populations and settings, 359–
361 substance use disorders and, 456–
457 treatment, 316–
333 issues specific to adolescents, 333
Educating & Supporting Inquisitive Youth in Recovery (ESQYIR), 630
Electrolyte abnormalities in eating disorders, 306t
Electronic health records (EHRs), 609–
610,
630
Electrophysiology in schizophrenia, 112–
121
Elevated symptoms of mania (ESM), 30
Emergency department self-harm prevention, 55–
56 suicide prevention interventions, 517–
519
(p. 871)
Emotion(s) brain circuitry for, developmental shifts, 204–
205 expressed, reduction, family therapy for, 139
Emotional processing in anxiety disorders, 200
Emotional Stroop task, 201–
202
Epidemiologic Catchment Area Study, 32
Escitalopram for major depressive disorder, 56,
59,
455
ESM (elevated symptoms of mania), 30
ESQYIR (Educating & Supporting Inquisitive Youth in Recovery), 630
Estrogen supplementation, in anorexia nervosa, 311
Ethical issues online treatment of mental disorders, 615
Ethnocultural factors in depression, 75–
76
Event-related potentials (ERPs) in anxiety disorders, 209 in schizophrenia contingent negative variation (CNV), 116,
117t mismatch negativity and post-onset progression of abnormalities, 114–
115
Evidence-based mental health services, 608–
618 policy, paradigm shifts in, 608–
610 care and care coordination, integration, 609 practice, paradigm shifts in, 612–
616 clinical decision making, 615–
616 family support services, 616 pediatric psychopharmacology, 613 research, paradigm shifts in, 610–
612 summary of changes in, 616–
617
Evidence-based practices for substance use disorders, 474–
475,
627–
628
Executive inhibitory circuitry defects in substance use disorder, 377
Exercise, weight-bearing, in anorexia nervosa, 311
Exposure and ritual prevention (EX/RP) for obsessive-compulsive disorder, 232,
233
Expressed emotions, reduction, family therapy for, 139
Extracurricular activities, positive youth development and, 556–
557
Extra-medical use of prescription medications, 390–
391,
392f
Extrapyramidal side effects in schizophrenia, 149
Facing the Odds gambling prevention program, 583t
Familial aggregation in schizophrenia, 124
Family-based interventions evidence-based practice, 616 in major depressive disorder, 80–
83
Family Check-Up program, 473
Family environment anorexia nervosa and, 341 eating disorders and, 321,
341 substance use disorders and, 465
Family-focused therapy (FFT) for bipolar disorder, 62–
63,
86
Family history bipolar disorder and, 30,
34 major depressive disorder and, 17
Family Smoking Prevention and Tobacco Control Act of 2009, 468
Family support specialists, 616
(p. 872)
Family therapy attachment-based, for major depressive disorder, 53 for bipolar disorder, 62–
63 for substance use disorders, 435–
436 for suicide attempters, 55
Fat, body, fear of, as criterion for anorexia nervosa, 291
Fear of body fat or weight gain, as criterion for anorexia nervosa, 291 brain circuitry for, developmental shifts, 204 food avoidance due to, 295 stranger, absence of, schizophrenia and, 170
Fear structures in anxiety disorders cognitive-behavioral therapy and, 214 emotional processing theory and, 200
Feeding problems, early, bulimia nervosa and, 344
FFT (family-focused therapy) for bipolar disorder, 62–
63
Financial crisis of 2008, 635
First (initial) onset, definition, 72
Five Cs of positive youth development, 548–
551
Fixed mindset, positive youth development and, 555
Fluid abnormalities in eating disorders, 306t
Fluoxetine for generalized anxiety disorder, 224 for major depressive disorder in children and adolescents, 59 with substance use disorder, 455–
456 for obsessive-compulsive disorder, 236 for post-traumatic stress disorder, 238 for selective mutism, 223 for suicide attempters, 528–
529
Flupenthixol for schizophrenia, 146t
Fluvoxamine for major depressive disorder, 56 for obsessive-compulsive disorder, 235–
236 for separation anxiety disorder, 227 for social anxiety disorder, 222
Follow-back studies in schizophrenia, 167,
172–
173
Frontal-temporal circuitry in schizophrenia, 121–
122
Functional MRI for anxiety disorders, 207–
208 electrophysiology versus, 112
Gamma-band activity in schizophrenia, 113–
114
Gammahydroxybutyrate (GHB), 424
Gang affiliation, anxiety disorders and, 261–
262
Gastrointestinal abnormalities in eating disorders, 306t
Gatekeeper training programs, 500–
502
Gateway theory of substance abuse, 462–
463
Gay, Lesbian and Straight Education Network (GLSEN), 513–
514
Gay-Straight Alliances (GSAs), 513–
514
GBG (Good Behavior Game), 467,
503
Gender differences substance use disorders, 463,
478
Generalized anxiety disorder, 223–
226
(p. 873)
treatment, 219t in children and adolescents, 224–
226 management of partial response and nonresponse to, 246
General liability theory for substance abuse, 463–
464
General Theory of Addiction, 581
Genes, susceptibility in substance use disorders, 385
Genetic counseling in schizophrenia, 130–
131
Genetics binge-eating disorder, 346
Genome scans in schizophrenia, 126
GHB (Gammahydroxybutyrate), 424
Global Burden of Disease Study, 349
Glucocorticoids in stress response, 40
Gonadal hormones, adolescent behavior and, 119
Good Behavior Game (GBG), 467,
503
Gratitude, positive youth development and, 553
Great Smoky Mountain Study bipolar disorder and, 32–
33,
34t
Group interventions, multiple family, 616
Growth hormone in major depressive disorder, 43
Growth mindset, positive youth development and, 555
Growth retardation in anorexia nervosa, 308
GSAs (Gay-Straight Alliances), 513–
514
Gymnastics, anorexia nervosa and, 341,
360
Haloperidol with lithium, for bipolar disorder, 66
Harm avoidance anorexia nervosa and, 377 anxiety disorder detection and screening, 266 eating disorders and, 337 vulnerability to depression and, 18–
19
Harm-minimization prevention programs, 581–
582
Headache, depression and, 17
Healthcare settings, screening for substance use disorders in, 622
Health insurance. See alsoMedicaid minor consent and confidentiality, 630
Help-Seeking behavior, stigma of mental illness and, 600–
602
Hematopoietic abnormalities in eating disorders, 306t
Heroin use behavioral therapy for, 436–
437 medications for long-term treatment, 447,
451 neurobiology of addiction, 372–
374
Heschl gyrus in schizophrenia, 114–
115
Hippocampus in anxiety disorders, 217 in suicidal behavior, 490
Hispanic Americans female suicide attempters, emergency department interventions, 518
Hooked City gambling prevention program, 583t
Hope, positive youth development and, 554
Hormone replacement therapy in anorexia nervosa, 311
HPG (hypothalamic-pituitary-gonadal) axis, 119
Hypokalemia in bulimia nervosa, 309
Hyponatremia in anorexia nervosa, 305
Hypophosphatemia in anorexia nervosa, 305,
310
Hypothalamic-pituitary-adrenal (HPA) axis axis activation in puberty, 119–
120 in schizotypal personality disorder, 120
Hypothalamic-pituitary-gonadal (HPG) axis, 119
ICD-10 (International Classification of Diseases, Tenth Revision),
100
Iceland, depression prevention program in, 79–
80
Imipramine for separation anxiety disorder, 227
Immunology in anxiety disorders, 207
Impulse control disorder in Internet addiction, 589–
590
Impulse control disorder in drug addiction, 374f
Impulsivity positive youth development, 550 substance use disorder, 382 suicidal behavior and, 489
Indicated prevention programs major depressive disorder, 77–
78
Infertility in anorexia nervosa, 308
Information processing in schizophrenia, event-related indices, 115–
119,
117t
Initial onset, definition, 72
Institute of Medicine, report on prevention of mental disorders, 71–
73,
76
Intelligence quotient in children of schizophrenic parents, 164,
164t
Interactive Screening Program, 499
Intermittent explosive disorder, 7
International Classification of Diseases, Tenth Revision (ICD- 10),
100
Internet addiction, xxiii,
586–
595 cognitive-behavioral model of, 588–
590 other addictions, compared, 588 other health correlates, 594 therapeutic interventions, 594–
595 type of Internet use and, 590–
591
Internet Addiction Test, 587
Internet-based relapse prevention, 329–
330,
332
Internet interventions/surveys evidence-based practice training, 614 stigma of mental illness, 600,
605 substance use disorder continuing care, 630
Interpersonal relationships alcohol use disorders and, 413–
414 suicidal behavior and, 491
Interpersonal therapy for bipolar disorder, with social rhythm therapy, 62 for major depressive disorder for suicide attempts, 54–
56
Interpretative threat bias in anxiety disorders, 202–
203
Interventions in adolescence. See also specific types, e.g., Cognitive-behavioral therapy
(p. 875)
Interview motivational, in substance use disorders, 439–
440,
473 psychiatric, in schizophrenia, 134–
135
Ipecac abuse in bulimia nervosa, 309
Juvenile justice system suicide prevention programs in, 512–
513
Kindness, positive youth development and, 553–
554
Lamotrigine for bipolar disorder, 67
LAMS (Longitudinal Assessment of Manic Symptoms) Study, 30–
31,
35–
36
Language delay in schizophrenia, premorbid abnormalities and, 161,
162t
Learning theories for anxiety disorders, 199–
201
Legal issues, suicidal behavior and, 492
Levomilnacipran for major depressive disorder, 56
Life Goals Program for bipolar disorder, 63
Life satisfaction, positive youth development and, 522–
553
Life Skills Training Program, 467,
473
Life stress, early hypothalamic-pituitary-adrenal axis hyperactivity, 40–
41 major depression and, 22–
25,
40
Lifetime morbid risk (LMR), 11
Linkage disequilibrium studies in schizophrenia, 126–
128
Linkage studies in substance use disorders, 385
Lisdexamfetamine for ADHD with substance use disorder, 454 for binge-eating disorder, 323
Lithium for anorexia nervosa, 322 for major depressive disorder, 58,
61 for suicide attempters, 528
Lithium for major depressive disorder, 58
LMR (lifetime morbid risk), 11
Locus ceruleus in anxiety disorders, 207
Locus coeruleus in anxiety disorders, 216
Longitudinal Assessment of Manic Symptoms (LAMS) Study, 30–
31,
35–
36
Lorazepam for schizophrenia, 147t
Loss-of-control eating, 347–
348
Love our Kids: Lock Your Guns program, 511
Loxapine for schizophrenia, 153t
LSD (lysergic acid diethylamide), 424–
425
Magnetic resonance imaging. See alsoFunctional MRI brain volumetric, in schizophrenia, 109–
112 morphometric, in anxiety disorders, 208
Magnetoencephalography in schizophrenia, 118–
119
Maintenance/interventions, definition, 72
Malnutrition, medical complications and, 305,
306t,
307
Maltreatment, depression and, 25,
34
Mandatory random drug testing, 467–
468
Mania. See alsoBipolar disorder comorbidities attention-deficit/hyperactivity disorder, 37 diagnostic criteria for, 30–
31
Marijuana use family-focused interventions for, 470
(p. 876)
mass media prevention campaigns for, 468–
469
Mass media drug abuse prevention campaigns, 468–
469 misinformation about mental illness, 602–
603 for reducing stigma of mental illness, 604–
605
Maternal depression offspring depression and, 17–
18,
27 response to cognitive-behavioral therapy and, 51
Maternal health, anorexia nervosa and, 338
Maternal-infant therapy for depression, 47–
48
Maudsley method in anorexia nervosa, 317–
318
Meaning, pursuit of, in positive psychology, 552
Medicaid family support services, 616 patient-centered medical homes and, 609 quality measures and, 610
Medical disorders, depression and, 17
Melancholic features, depression with, 8
Menarche, early, bulimia nervosa and, 343
Mental health disorders. See also specific disorders, e.g., Anxiety disorders
confidentiality issues, 499 future and pressing issues for national youth development strategy, 636–
637 gambling behavior and, 577 stigma of, 600–
606 in community attitudes, 601 factors contributing to, 601–
603 treatment impact of stigmatization, 601–
603
Mental Health Services Act of 2004, 605
Milnacipran for major depressive disorder, 56
Mindset, positive youth development and, 554–
555
Minnesota Twelve-Step model for substance use disorders, 440
Minor consent for services, 630–
631
Mirtazapine for major depressive disorder, 57–
58,
60–
61
Molecular genetic studies in schizophrenia, 130
Molindone for schizophrenia, 146t,
153t
Monoamine oxidase inhibitors (MAOIs) for major depressive disorder, 57,
58,
455
Mood stabilizers. See also specific drugs, e.g., Lithiumfor bipolar disorder combination therapy, 66–
67
MPH-SODAS (Spheroidal Oral Drug Absorption System), 454
Multidimensional Anxiety Scale for Children (MASC), 266
Multidimensional family therapy for substance use disorders, 436
Multiphase Optimization Strategy (MOST), 474
Multisystemic therapy for substance use disorders, 435
Mutism, selective maintenance of gains, 243
Naltrexone for alcohol use disorders, 446,
450 for opioid addiction, 451
National Annenberg Risk Survey of Youth (NARSY), 601
National Comorbidity Survey (NCS) bipolar disorder and, 32–
33 substance use disorders and, 445
National Comorbidity Survey Replication (NCS-R), 11,
260,
297,
343
National Health and Nutrition Examination Survey (NHANES), 5t,
11,
12t,
16,
35
National Household Survey on Drug Use and Health (NHSDUH), 389–
390
National Institute of Health, 636
National Institute of Mental Health (NIMH) on anxiety disorder treatments, 218 Center for Prevention Research, 71 depression diagnosis and, 4 history of prevention in mental health and, 70–
71 Research Domain Criteria (RDoC) of, 364,
636 substance use disorder research of, 442
National Network of Child Psychiatry Access Programs, 613
National Surveys on Drug Use and Health (NSDUH) on children of substance abusing parents, 429 on current trends in drug use, 389–
392 on prescription pain relievers, 395
National Youth Anti-Drug Media Campaign, 469
National youth development strategy, 636–
637
Native Americans suicide prevention programs for, 508–
509
Nefazodone for major depressive disorder, 60
Negative affectivity and vulnerability to depression, 18–
19
Negative cognitions interpersonal relationships and, 25 suicidal behavior and, 489 vulnerability to depression and, 20–
22
Negative life events anorexia nervosa and, 341 suicidal behavior and, 490–
492
Negative self-talk, anxiety disorders and, 215
Negative symptoms in schizophrenia, 105
Neuregulin 1 as schizophrenia susceptibility gene,
128
Neuroanatomic studies in schizophrenia, 109–
112
Neurobehavioral deficits in schizophrenia, 106–
109
Neurobiology binge-eating disorder and, 346–
347 substance use disorders and, 372–
382 suicidal behavior and, 490
Neurochemistry, anxiety disorders and, 207
Neurocognitive functioning in anorexia nervosa, 337
(p. 878)
Neuroendocrine changes in eating disorders, 306t
Neuroimaging in substance use disorders, 379–
382
Neuroleptic augmentation for OCD, 247
Neurologic signs in schizophrenia, premorbid abnormalities, 169t,
170,
172,
173
Neuropsychological deficits in children of schizophrenic parents, 177
Neuroticism anxiety disorders and, 210,
256 as risk factor for psychopathology, 19 and vulnerability to depression, 18–
19
Neurotransmitter systems. See also specific types, e.g., Serotoninin anxiety disorders, 217 in substance use disorders, 374–
376
A New State of Mind: Ending the Stigma of Mental Illness (film), 605
NHSDUH (National Household Survey on Drug Use and Health), 389–
390
Nicotine receptors, smoking and, 383
Nicotine-replacement therapy (NRT), 446,
449
Nigrostriatal pathway and motor dysfunction in schizophrenia, 107
Novelty, amygdala response to, 205–
206
Np (processing negativity) in schizophrenia, 116–
118,
117t
Obesity anorexia nervosa and, 338 binge-eating disorder and, 347 as risk factor for eating disorders, 359
Obsessive-compulsive disorder (OCD) in children and adolescents, 232–
238 signs and symptoms of, 193t treatment in children and adolescents, 233–
238 management of partial response and nonresponse to, 247–
248
Obstetrics-gynecology, detection and screening of anxiety disorders and, 268
Olanzapine for major depressive disorder, 58 for post-traumatic stress disorder, 248 for treatment-resistant depression, 527–
528
Ondansetron for bulimia nervosa, 323
Onset first (initial), definition, 72 risk of, versus risk of relapse, 73
Opening Minds program, 606
Opioid abuse behavioral therapy for, 436–
437 medications for long-term treatment, 451
Opioid pain relievers, 394–
397
Oppositional defiant disorder (ODD) anxiety disorder and, 198,
203 disruptive mood dysregulation disorder and, 7 substance use disorder and, 429
Oregon Adolescent Depression Project Study bipolar disorder and, 33,
34t
Orlistat for binge-eating disorder, 323
Osmotic-release oral system methylphenidate (OROS-MPH) for ADHD plus substance use disorder, 453
Oxcarbazepine for bipolar disorder in adolescents, 64t
P1/N1 asymmetry in schizophrenia, 116–
118,
117t
P50-early sensory gating endophenotype in schizophrenia, 114,
129–
130
P300 (late positive component) in schizophrenia, 115,
116–
118,
117t
PACE (Personal Assessment and Crisis Evaluation) clinic, 135–
136
Pacific Islanders, suicide rate of, 485
Pain relievers, opioid, 394–
397
Panic attacks, neuroticism and, 19
Panic disorder in children and adolescents, 230–
231 signs and symptoms of, 193t suicidal behavior and, 488 treatment, 219t in children and adolescents, 230–
231 maintenance of gains, 244 management of partial response and nonresponse to, 246–
247
Parent(s) depressed and response to cognitive-behavioral therapy, 51 firearms counseling programs for, 510–
512 gambling behavior of, 576 substance use by, and offspring substance use, 429 suicidal, and offspring suicide, 489–
490
Parent-child interaction in Internet addiction, 593–
594
Parenting dimension in alcohol use disorders, 413–
414
Parietal circuitry in schizophrenia, 121–
122
Paroxetine for anxiety disorders, 22,
236 for major depressive disorder for post-traumatic stress disorder, 238 for social anxiety disorder, 243
Partnership for Drug-Free Kids, 469
Patient-centered medical homes (PCMHs)/health homes, 609
Patterson’s developmental theory of substance abuse, 464–
465,
465f
Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act of 2008 (MHPAEA), xxiii–
xxiv,
608,
617,
621,
634
Peer relations alcohol use disorders and, 413–
414 anxiety disorders and, 260–
261 binge-eating disorder and, 348 in children of schizophrenic parents, 172,
174 evidence-based practice for, 616 substance use disorder and, 384
Penn Resiliency Program, 77–
78,
558b
Perfectionism anxiety disorders and, 222
Performance-limited social anxiety, 192,
195
Perinatal events anorexia nervosa and, 338
Perseverance, positive youth development and, 554
(p. 880)
Persistent depressive disorder lifetime prevalence of, 13 major depressive disorder and, 9–
10
Personal Assessment and Crisis Evaluation (PACE) clinic, 135–
136
Personal Growth Class (PGC), 516
Personality anxiety disorders and, 210,
256 of children of schizophrenic parents, 177 genetic contributions to, 210 major depressive disorder and, 18–
20 suicidal behavior and, 489
Personality disorder(s) anorexia nervosa and, 302 borderline, plus suicidal behavior, dialectical behavioral therapy for, 522 schizotypal, 100,
177 movement abnormalities, 107
Pessimistic attributional style suicidal behavior and, 489 vulnerability to depression and, 20–
22
PGC (Personal Growth Class), 516
Pharmacotherapy for anxiety disorders with cognitive-behavioral therapy, 218–
219 for binge-eating disorder, 331 for bipolar disorder combination therapy, 66–
67 drug interactions and, 456–
458 evidence-based practice and, 613 for generalized anxiety disorder, 219t,
224 for Internet addiction, 595 for post-traumatic stress disorder, 219t,
238,
242 for selective mutism, 219t,
223 for separation anxiety disorder, 219t,
227 for suicide attempters, 526–
531
Phenelzine for social anxiety disorder, 243
Phobia in children and adolescents, 228–
229 signs and symptoms of, 194–
195t treatment, 219t in children and adolescents, 228–
229 maintenance of gains, 244 management of partial response and nonresponse to, 246
Physical abuse, suicidal behavior and, 490–
491
Physicians anxiety disorders, monitoring for symptoms of, 268 eating disorders, treatment of, 322 inpatient detoxification and, 447–
448 integrated care and care coordination with, 609 SSRI antidepressant risk monitoring, 92,
528–
529 substance use disorders, screening for, 622,
624
Pimozide for schizophrenia, 146t,
152t
Pindolol, augmentation effect, in panic disorder, 247
Political interventions, xxiii–
xxiv for evidence-based practice, 608–
610 for firearm restriction, 635–
636 for prevention of major depressive disorder, 88 for substance use disorder treatments, 620–
621
Population stratification artifact, 127
Positive Action Program, 558b
(p. 881)
Positive and Secondary Control Enhancement Therapy (PASCET), 51
Positive psychology as goal of prevention programs, 73,
566 individual characteristics, 553–
555 as outcome target for anxiety prevention studies, 275 positive youth development field, integration with, 547,
551–
555
Positive rehabilitation, 565–
566
Positive relationships, 552
Positive youth development, xxiii,
544–
568 for at-risk and troubled youth, 564–
566 future directions for, 563–
566 natural history studies, 563–
564 positive psychology movement, integration with, 547,
551–
555 problem-centered approaches versus, 546–
547 for substance abuse prevention, 474
Positron emission tomography (PET), 105,
112
Postpartum depression, 47–
48
Post-traumatic stress disorder alcohol use disorders and, 415 in children and adolescents, 238–
239 signs and symptoms of, 194t trauma exposure, adolescence and, 262–
263 treatment, 219t in children and adolescents, 239–
242 maintenance of gains, 245 management of partial response and nonresponse to, 248
Prefrontal cortex developmental changes in, 204 suicidal behavior and, 490
Prefrontal-striatal circuitry in schizophrenia, 121–
122
Premature birth, anorexia nervosa and, 338
Premenstrual dysphoric disorder, 10–
11
Prevention. See also specific disorders
Problem behavior theory of substance abuse, 463–
464
Problem-centered approach to youth development, 546–
547
Problem-solving therapy for anxiety disorders, 215 for major depressive disorder, 48–
49 for suicidal adolescents, 502–
503
Procyclidine for schizophrenia, 152t
Promoting Alternative Thinking Strategies program, 558b
Protective factors, definition, 73
Psychiatric interview in schizophrenia, 134–
135
Psychiatric symptoms in schizophrenia, premorbid abnormalities, 168,
169t,
171–
172
Psychiatry for detection and screening of anxiety disorders, 268–
269
Psychobehavioral influences in alcohol use disorders, 414
Psychodynamic therapy, brief, for major depressive disorder, 48
Psychoeducation. See alsoTraining for anxiety disorders, 215 for bipolar disorder, 62–
63 for reducing stigma of mental illness, 603 for suicide prevention, 498–
505
Psychological characteristics of positive youth development, 551–
555
Psychological debriefing, 278
Psychological factors in smoking, 421
Psychosocial assessment in schizophrenia, 101–
102
Psychosocial rehabilitation, 566
Psychosocial therapy. See also specific types, e.g., Cognitive-behavioral therapy for bipolar disorder, 62–
63 for Internet addiction, 594–
595 for major depressive disorder in children and adolescents, 50–
61 for selective mutism, 219t,
223 for separation anxiety disorder, 219t,
226–
227 for suicide attempters, 520–
525
Psychoticism in schizophrenia, 105
Pubertal delay in anorexia nervosa, 308
Pubertal status anorexia nervosa and, 338 major depressive disorder and, 6–
8
Purpose, positive youth development and, 552
Quality indicators of mental health services, 609–
610,
616
Quantum Opportunities Program, 558b
Question Persuade Refer (QPR), 501–
502
Quetiapine for anorexia nervosa, 322 for major depressive disorder, 58 for treatment-resistant depression, 528
Race/ethnicity. See also specific races and ethnicities access to mental health services and, 613 Internet addiction and, 591–
592
Rapid Response (RR) emergency department intervention for suicidal adolescents, 518
Rating scales for anxiety disorders, 264–
269
RCMAS (Revised Children’s Manifest Anxiety Scale), 266
RDoC (Research Domain Criteria), 364,
636
(p. 883)
Reboxetine for major depressive disorder, 57
Reconnecting Youth (RY) Prevention Research Program, 472,
516
Refeeding in anorexia nervosa, 310
Referral practices, school-based health centers and, 624
Rehabilitation, positive, 565
Relaxation exercises for anxiety disorders, 215
Repetitive transcranial magnetic stimulation (rTMS), 61
Research agendas evidence-based mental health services, 610–
612 major depressive disorder, 90–
94 substance use disorders, 478–
479
Research Domain Criteria (RDoC), 364,
636
Resiliency in children of depressed parents, 80–
81 gambling behavior and, 578,
582 as goal of prevention programs, 73 as outcome of positive youth development, 548
Resourceful Adolescent Parenting Program (RAP-P), 55,
524
Respiratory system in panic disorder, 206,
254
Restricting subtype of anorexia nervosa, 291,
292b
Restrictive food intake disorder, 295
Retrospective studies in schizophrenia, 167,
172–
173
Revised Children’s Manifest Anxiety Scale (RCMAS), 266
Reward center dysregulation
Risk factors, definition, 72–
73
Risk of onset versus risk of relapse, 73
Risperidone for anorexia nervosa, 322 augmentation effect, in obsessive-compulsive disorder, 247 for conduct disorder with substance use disorder, 456 for obsessive compulsive disorder, 247
Ritual prevention for obsessive-compulsive disorder, 232,
233
rTMS (repetitive transcranial magnetic stimulation), 61
Sample size for prevention studies, 86
SBIRT (Screening, Brief Intervention, and Referral to Treatment) projects, 622–
625
Schizophrenia, xxiii adolescent-onset, developmental precursors, 165–
180 brain circuitry in, 121–
123 implications for adolescence, 123 brain developmental abnormalities and, 165,
177 comorbid syndromes, adjunctive treatments, 149–
150 diagnostic criteria for, 100–
101 duration of untreated psychosis, outcome and, 135,
155 early interventions preventive strategies, 134–
136 emotion-processing deficits, 108 endophenotypes definitions based on, 105 molecular genetic studies, 130 genetic studies, 124–
131,
177–
178 and disease mechanisms, 128–
129 of familial aggregation, 124 of psychiatric disorders transmitted, 125–
126 magnetoencephalography, 118–
119 neuroanatomic studies on, 109–
112 neurobehavioral deficits and, 106–
109 neuroendocrinology and, 119–
121 pathophysiology, in adolescence, 123–
124 positive symptoms, pharmacotherapy, 149 premorbid abnormalities, 159–
165 birth cohort studies, 166,
172 consistency of findings, 172–
173 implications for preventive intervention, 175–
176 research strategies to identify, 167–
174 and vulnerability hypothesis, 165 psychosocial assessment, 101–
102 psychosocial treatment, 134–
142,
151 cognitive remediation therapy, 137–
138 interpersonal therapy, 138 social skills training, 138–
139 residual symptoms, adjunctive treatments, 149–
150 risk factors for developmental perspective, 167–
174 and prevention strategies, 158 suicidal behavior and, 150 symptoms of dimensional groupings, 105
Schizotypal personality disorder children of schizophrenic parents and, 177 movement abnormalities, 107
Schools. See alsoColleges drug testing programs, 467–
468 educational interventions for reducing stigma of mental illness, 603,
606 social anxiety disorder, 222 training for staff in, 628,
634 treatment programs, suicide attempters, 516–
517
Screen for Child Anxiety Related Emotional Disorders, 266
Screening in psychiatric care settings, 268–
269 substance use disorders, 621–
625
Screening, Brief Intervention, and Referral to Treatment (SBIRT) projects, 622–
625
Seasonal affective disorder, 9
Seattle Social Development Project, 559b
Selective mutism maintenance of gains, 243
Selective prevention programs for anxiety disorders, 272–
273 for suicidal behavior, 508–
514
Selective serotonin reuptake inhibitors (SSRIs) for anxiety disorders, 210,
456 and depression after exposure to child abuse, 24 for generalized anxiety disorder, 225–
226 for major depressive disorder, 56 in children and adolescents, 52,
59–
60 with substance use disorder, 455–
456 for obsessive-compulsive disorder, 235–
236 for post-traumatic stress disorder, 238,
242 for separation anxiety disorder, 227
Selegiline transdermal system, 60
Self-control, positive youth development and, 550,
554
Self-image and self-esteem programs, 359–
361
Seligman program for prevention of depression, 77–
78
Sensory gating in schizophrenia, 114,
129–
130
Separation, depression and, 22
Separation anxiety disorder signs and symptoms of, 194t
Septal-hippocampal system in anxiety disorders, 217
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, 57
Serotonin in anxiety disorders, 217 in binge-eating disorder, 346 impulsive behavior and, 383 in suicidal behavior, 490
Sertraline for generalized anxiety disorder, 224 for major depressive disorder in children and adolescents, 59,
60–
61 with substance use disorder, 455 for obsessive-compulsive disorder, 236–
237 for post-traumatic stress disorder, 238,
242,
248 for social anxiety disorder, 243
Service delivery systems for substance use disorders, 620–
631
Sexual abuse anorexia nervosa and, 341 cognitive-behavioral therapy, response to, 51 post-traumatic stress disorder and, 239–
240 suicidal behavior and, 491–
492
Sexual assault, depression and, 24
Sexual behaviors, high-risk, alcohol-related, 411
Short stature in anorexia nervosa, 308
Sibling influences in alcohol use disorders, 414
Signs of Suicide (SOS) program, 501
Skeletal abnormalities in eating disorders, 306t
Skills, Opportunities, and Recognition program, 559b
Skills training for suicide prevention, 502–
503
Skin abnormalities in eating disorders, 306t
Sleep, Internet addiction and, 594
Smoking anxiety disorders and, 260–
261 communication of risks and nicotine dependence, 417–
419 mass media prevention campaigns for, 468–
469 price interventions for, 469 socioenvironmental factors and, 420–
421
Social anxiety disorder. See alsoSelective mutism in children and adolescents, 220–
221 Internet addiction for coping with, 589 signs and symptoms of, 194t treatment, 219–
223,
219t in children and adolescents, 221–
222 maintenance of gains, 243 management of partial response and nonresponse to, 246
Social Anxiety Scale for Children-Revised, 267
Social barriers to care, 352–
353
Social cognitive functioning in anorexia nervosa, 337
Social Phobia and Anxiety Inventory for Children, 267
Social rhythm therapy, interpersonal therapy with, for bipolar disorder, 62
Social skills deficits Internet addiction and, 589–
590 as protective factor in suicide, 495 training for major depressive disorder, 53 for suicidal behavior, 502–
503
Social support anxiety disorders and, 263–
264
Societal factors in alcohol use disorders, 413
Socioeconomic status. See alsoPoverty
Socioenvironmental factors in smoking, 420–
421
Sociotropy, depression and, 24–
25
SoCRATES (Study of Cognitive Reality Alignment Therapy in Early Schizophrenia), 137
SOS (Signs of Suicide) program, 501
Span of apprehension, schizophrenia and, 170,
171f
Spence Children’s Anxiety Scale, 266
Spheroidal Oral Drug Absorption System (MPH-SODAS), 454
Sports participation substance use disorder and, 384
Stacked Deck gambling prevention program, 583t
Stature, short, in anorexia nervosa, 308
Steps to Prevent Firearms Injury Program (STOP), 512
Stigma of mental illness, 600–
606 anxiety prevention programs and, 278–
279 in community attitudes, 601 factors contributing to, 601–
603
(p. 887)
programs for reduction of, 605–
606
STOP (Steps to Prevent Firearms Injury Program), 512
Stranger fear, absence of, schizophrenia and, 170
Strengthening Families Program, 471
Streptococcal prophylaxis for PANDAS, 237
Stress anxiety disorders and, 216–
217 hypothalamic-pituitary-adrenal axis hyperactivity and, 40–
41 Internet addiction and, 593–
594 major depressive disorder and, 22–
25,
40 prepartum exposure to, 23 suicidal behavior and, 493
Stress-diathesis model of depression, 20–
22
Striatal-prefrontal circuitry in schizophrenia, 121–
122
Striatum and motor dysfunction in schizophrenia, 107
Study of Cognitive Reality Alignment Therapy in Early Schizophrenia (SoCRATES), 137
Subjective well-being, positive youth development and, 551–
553
Substance use. See also specific name of substance drug testing programs, 467–
468 parental substance use and, 429
Substance use disorders. See also specific name of substance in animal models of conditioned drug effects, 376 brain executive inhibitory circuitry defects, 377 brain reward center dysregulation, 376 clinical aspects of, 394–
426 “ecstasy” (MDMA) and, 422 comorbidities attention-deficit/hyperactivity disorder, 453–
454 binge-eating disorder, 348 special considerations, 456–
458 developmental theories of, 462–
466 drug-related cues and, 380–
382 Internet addiction for coping with, 588–
589 neuroadaptations for, 376 pharmacotherapy, 444–
457 abstinence and relapse prevention, 448 to reduce drug reward and craving, 446 prevention programs for, xxii–
xxiii,
466–
473 community environmental interventions, 470 environmental universal interventions, 468–
470 future directions and challenges, 473–
475 genetics knowledge, applying, 472–
473
(p. 888)
model, summaries and reviews, 473–
475 school-based universal interventions, 466–
468 theoretical and conceptual models, 460,
461f psychosocial therapy, 430–
444 disease model approaches, 440 motivational approaches, 439–
440 multisystem approaches, 435–
436 outpatient approaches, 432–
433 process research and mechanisms of action, 440–
441 randomized clinical trials, 433–
434 risk factors and protective factors for, 460–
462 screening for, 621–
625 in healthcare settings, 622 treatment, 428–
457 acute versus chronic care, 621 service delivery systems, 620–
631 trends in adolescents Seeking, 392–
393f vulnerability to D2 dopamine receptors and,
379–
380
Suicide and suicidal behavior, xxiii anorexia nervosa and, 304 firearms availability and, 494 gender differences in, 485 prevention programs for ecological and comprehensive approaches, 503–
505 gatekeeper training programs, 500–
502 in juvenile justice systems, 512–
513 Native American youth and, 508–
509 posthospitalization programs, 519–
520 psychotherapy and psychosocial therapy, 520–
525 school-based programs for suicidal students, 516–
517 suicide awareness and education, 498–
505 youth exposed to suicide and, 509–
510 protective factors for, 494–
495 racial/ethnic differences in, 485 risk factors for, 488–
494 availability of means, 494–
495 behavioral and personality factors, 489 previous suicidal behavior, 489 social-behavioral skills, 495 scope and demographics of, 484–
485f summary of knowledge about, 534–
535 treatment programs psychotherapy and psychosocial therapy, 55–
56,
520–
525 violence exposure and, 75
(p. 889)
Surgeon General’s report on mental health, 72
Surveys. See also specific surveys
Susceptibility genes in substance use disorders, 385
Teasing, binge-eating disorder and, 348
Teen Health2000 Study
bipolar disorder and, 33,
34t
Telephone help lines, 600
Television. See alsoMass media adolescent viewing time, 603 for reducing stigma of mental illness, 604–
605
Temporal-frontal circuitry in schizophrenia, 121–
122
Test Anxiety Scale for Children, 268
Tetrahydrocannabinol (THC), 401
Therapeutic community for substance use disorders, 429
Threat, amygdala response to, 205–
206
Threat bias in anxiety disorders
Time to Change (TTC) program, 605
TIPs (Treatment and Intervention in Psychosis) project, 135–
136
Topiramate for bulimia nervosa, 323
TORDIA (Treatment of SSRI-Resistant Depression in Adolescents) study, 52,
61
Training. See alsoPsychoeducation evidence-based practice identification of pediatric mental health conditions, 613,
617 on identification of substance use disorder, 625 social skills for major depressive disorder, 53 suicidal behavior, gatekeeper training programs, 500–
502
Tranylcypromine for major depressive disorder, 58
Trauma exposure, anxiety and, 262–
263
Treatment and Intervention in Psychosis (TIPs) project, 135–
136
Treatment of Adolescent Depression Study (TADS), 51,
54,
59,
91–
92
Treatment of mental health disorders. See also specific disorders impact of stigmatization on, 601–
603 research developments in, xxii
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study, 52,
61
Tricyclic antidepressants for generalized anxiety disorder, 224,
225 for major depressive disorder in adults, 57
Trifluoperazine for schizophrenia, 146t,
152t
Trihexyphenidyl for schizophrenia, 148t
Triiodothyronine for major depressive disorder, 58
Triple-P (Positive Parenting Program), 473
TTC (Time to Change) program, 605
Twelve-Step Minnesota model, 440
Twin studies in substance use disorders, 384–
385
Universal prevention programs for anxiety disorders, 273–
274 for major depressive disorder, 78 for substance use disorders, 466–
467
University of Illinois, suicide attempter treatment programs of, 525
Venlafaxine for generalized anxiety disorder, 22,
226 for suicidal behavior, 527,
530
(p. 890)
Verbal memory deficit in children of schizophrenic parents, 170–
171
Vietnam War, drug use and, 388
Violence, exposure to post-traumatic stress disorder and, 75,
238–
239
Vitamin D supplementation, in anorexia nervosa, 311
Vortioxetine for major depressive disorder, 57
Wanna Bet? gambling prevention program, 583t
Webinars for evidence-based practice, 614
Weight-bearing exercise in anorexia nervosa, 311
Weight gain fear of, as criterion for anorexia nervosa, 291 inappropriate behaviors to prevent, as criterion for bulimia nervosa, 292
Weight loss. See alsoDieting binge-eating disorder, 323 as criterion for anorexia nervosa, 291
Weight restoration for eating disorders, 312,
322
Well-being, positive youth development and, 551–
553
World Health Organization, 349,
617
Youth development bio-ecological approach, 546 problem-centered approach, 546–
547
Youth Gambling: An Awareness and Prevention Workshop, 583t
Youth Making Choices gambling prevention program, 583t
Youth-Nominated Support Team (YST) for suicide attempters, 519–
520
Youth Risk Behavior Surveillance System, eating disorders and, 301
Youth Suicide Prevention and Intervention Program, 504
Zero-tolerance policies, 622–
623
Zinc supplementation for anorexia nervosa, 322
Ziprasidone for bipolar disorder, 64t,
65
Zuni Life Skills Curriculum, 508